clinical trial · NCT05133297
The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis
Hangzhou Highlightll Pharmaceutical Co., Ltd·phase2·completed·n = 101
Rheumatoid ArthritisTLL-018TLL-018TLL-018Tofacitinib
brief summary
This is a randomized, double-blind, double-dummy, tofacitinib-parallel-group, phase 2A study to assess the safety and efficacy of TLL-018 in active rheumatoid arthritis subject who had an inadequate response or intolerance to methotrexate.
started
Feb 16, 2022
primary completion
Dec 19, 2022
completion
May 30, 2023
last updated
Sep 5, 2023
official title
A Phase 2A, Randomized, Double-blind, Double-dummy, Tofacitinib-parallel-group Study to Evaluate the Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis Who Had an Inadequate Response or Intolerance to Methotrexate.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol